Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin versus NPH insulin add-on to glimepiride in type 2 diabetes
2012-001143-46Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin add-on to glimepiride with NPH insulin add-on to glimepiride (2 arms). Primary endpoint: Composite glycemic target without hypoglycemia or weight gain. Started Apr 2012; status: completed.
02
Drugs
vildagliptininsulin isophaneglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-001143-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001143-46.